Citius Pharmaceuticals is trading at $0.52, down 5.21%, with no fresh company-specific announcement identified to explain the September 29 pre-market decline. - U.S. stocks were pressured on September 28 by higher oil prices and Treasury yields. - September 29 futures were modestly higher, and that context does not clearly explain the decline. - Available evidence does not establish a specific catalyst or confirm a link to broader-market sentiment.